Drug Safety Update

Isotretinoin – changes to prescribing guidance and additional risk minimisation measures

Issued 22 Jan 2026

Read and act on the official notice on GOV.UK

The MHRA's summary

The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin, following a review of the impact of the measures implemented in 2023. We ask healthcare professionals to review these new measures and supporting materials and integrate them into their clinical practice.

MHRA's audience tags: Dermatology, Dispensing GP practices, General practice, Pharmacy, Psychiatry

Pharmshark is not an official alerting route. Make sure your pharmacy receives alerts directly from the MHRA and through your organisation, and always act on the official GOV.UK notice.

Source: the MHRA on GOV.UK. Contains public sector information licensed under the Open Government Licence v3.0. Pharmshark is not affiliated with or endorsed by the MHRA.